查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1872263

標靶RNA定序：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Targeted RNA Sequencing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 107 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球標靶 RNA定序市場在2024年達到 22.94億美元，預計到2031年將達到 77.81億美元，2025年至2031年的年複合成長率為 18.7%。

標靶RNA定序是一種分子生物學技術，它利用高通量定序定量分析特定基因或基因區域的表達。與全轉錄組定序不同，標靶RNA定序致力於特定的基因組，具有成本低、靈敏度高、資料處理簡化等優勢。它廣泛應用於癌症分型、免疫微環境分析、藥物標靶識別、遺傳疾病診斷和單細胞表達分析等領域。隨著定序平台的普及以及多重PCR和探針雜合反應技術的進步，標靶RNA定序已成為臨床研究機構和生物技術公司在精準表達分析領域中常規且強大的工具。

隨著個人化治療理念的深入和精準醫療的進步，靶向RNA定序的需求持續成長，尤其是在癌症和遺傳疾病領域。政府主導的各項措施以及製藥巨頭對生物標記開發和生物資訊學的持續投入，加速該技術在科研機構和商業設施中的應用。 Illumina和Thermo Fisher等公司報告指出，其靶向定序panel的收入年複合成長率穩定在20%以上，凸顯了該技術在基因組學服務組合中日益重要的地位。美國、中國和歐洲政府對生命科學領域的投入激增，也進一步推動了市場的發展。

儘管前景可觀，但市場仍面臨諸多挑戰，例如複雜的資料解讀、缺乏工作流程標準化以及樣本製備的技術敏感性。高通量定序平台價格依然高成本，這為小規模實驗室和機構的應用設置了障礙。此外，日益嚴格的法規結構，包括體外診斷（IVD）認證和臨床實驗室改進修正案（CLIA）合規性，也延長了臨床應用的時間。競爭壓力也不斷加劇，價格成為決定性因素，並將議價能力集中在主要參與者之間。

下游需求主要由癌症研究機構、生物製藥公司和第三方合約研究組織（CRO）服務供應商驅動。癌症篩檢、液態生物檢體和免疫療法目標開發的進步推動對基於 RNA 的伴隨診斷的日益依賴。據投資銀行報告顯示，標靶表達譜分析在 RNA定序市場的佔有率不斷成長，預計未來五年內將滲透到固態腫瘤診斷、兒童罕見疾病分析和細胞治療生產品管等高價值領域。

本報告目的是依地區/國家、類型和應用對全球靶向 RNA定序市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以銷售收入為基準年（2024年），對標靶 RNA定序市場規模、估算和預測進行了呈現，並包含了2020年至2031年的歷史資料和預測資料。報告採用定量和定性分析相結合的方法，目的是幫助讀者制定業務/成長策略，評估市場競爭格局，分析公司在當前市場中的地位，並就靶向 RNA定序做出明智的商業決策。

市場區隔

公司

  • Thermo Fisher
  • Illumina
  • Roche Holdings
  • BGI
  • Eurofins
  • LabCorp
  • Berry Genomics
  • Macrogen
  • GENEWIZ
  • Natera
  • Novogen
  • Pacific Biosciences
  • Oxford Nanopore

依類型

  • EXOME定序
  • 富集定序
  • 擴增子定序

依應用

  • 研究機構
  • 醫院和診所
  • 生技公司
  • 診斷檢查室

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Targeted RNA Sequencing was estimated to be worth US$ 2294 million in 2024 and is forecast to a readjusted size of US$ 7781 million by 2031 with a CAGR of 18.7% during the forecast period 2025-2031.

Targeted RNA Sequencing is a molecular biology technique that uses high-throughput sequencing to quantitatively analyze the expression of specific genes or gene regions. Unlike whole transcriptome sequencing, targeted RNA sequencing focuses on a defined gene panel, offering advantages such as lower cost, higher sensitivity, and simplified data processing. It is widely used in cancer subtyping, immune microenvironment profiling, drug target identification, genetic disease diagnostics, and single-cell expression analysis. With the proliferation of sequencing platforms and the advancement of multiplex PCR and probe hybridization technologies, targeted RNA sequencing has become a routine and powerful tool for clinical research institutions and biotech companies in the field of precision expression analysis.

As the concept of personalized treatment deepens and precision medicine advances, demand for targeted RNA sequencing continues to grow, especially in cancer and genetic disease applications. Government initiatives and sustained investments from pharma giants in biomarker development and bioinformatics are accelerating technology adoption in research labs and commercial institutions. Companies like Illumina and Thermo Fisher have reported a consistent CAGR of over 20% in targeted sequencing panel revenues, highlighting its growing role in genomic service portfolios. National funding surges in life sciences across the U.S., China, and Europe are further energizing the market.

Despite the promising outlook, the market faces challenges such as complex data interpretation, lack of standardization in workflows, and technical sensitivity to sample preparation. High-throughput sequencing platforms remain costly, creating adoption barriers for smaller labs and institutions. Additionally, increasingly stringent regulatory frameworks (e.g., IVD certifications, CLIA compliance) have extended timelines for clinical applications. Competitive pressure is also rising, with pricing becoming a pivotal factor and bargaining power concentrated among leading players.

Downstream demand is primarily driven by cancer research institutes, biopharma companies, and third-party CRO service providers. With the rise of cancer screening, liquid biopsy, and immunotherapy target development, the reliance on RNA-based companion diagnostics is intensifying. According to investment bank reports, targeted expression profiling is expanding its share within the RNA sequencing market and is expected to penetrate high-value segments such as solid tumor diagnostics, pediatric rare disease analysis, and quality control in cell therapy manufacturing over the next five years.

This report aims to provide a comprehensive presentation of the global market for Targeted RNA Sequencing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Targeted RNA Sequencing by region & country, by Type, and by Application.

The Targeted RNA Sequencing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted RNA Sequencing.

Market Segmentation

By Company

  • Thermo Fisher
  • Illumina
  • Roche Holdings
  • BGI
  • Eurofins
  • LabCorp
  • Berry Genomics
  • Macrogen
  • GENEWIZ
  • Natera
  • Novogen
  • Pacific Biosciences
  • Oxford Nanopore

Segment by Type

  • Exome Sequencing
  • Enrichment Sequencing
  • Amplicon Sequencing

Segment by Application

  • Research Institutes
  • Hospitals & Clinics
  • Biotechnology Company
  • Diagnostic Lab

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Targeted RNA Sequencing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Targeted RNA Sequencing Product Introduction
  • 1.2 Global Targeted RNA Sequencing Market Size Forecast (2020-2031)
  • 1.3 Targeted RNA Sequencing Market Trends & Drivers
    • 1.3.1 Targeted RNA Sequencing Industry Trends
    • 1.3.2 Targeted RNA Sequencing Market Drivers & Opportunity
    • 1.3.3 Targeted RNA Sequencing Market Challenges
    • 1.3.4 Targeted RNA Sequencing Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Targeted RNA Sequencing Players Revenue Ranking (2024)
  • 2.2 Global Targeted RNA Sequencing Revenue by Company (2020-2025)
  • 2.3 Key Companies Targeted RNA Sequencing Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Targeted RNA Sequencing Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Targeted RNA Sequencing
  • 2.6 Targeted RNA Sequencing Market Competitive Analysis
    • 2.6.1 Targeted RNA Sequencing Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Targeted RNA Sequencing Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted RNA Sequencing as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exome Sequencing
    • 3.1.2 Enrichment Sequencing
    • 3.1.3 Amplicon Sequencing
  • 3.2 Global Targeted RNA Sequencing Sales Value by Type
    • 3.2.1 Global Targeted RNA Sequencing Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Targeted RNA Sequencing Sales Value, by Type (2020-2031)
    • 3.2.3 Global Targeted RNA Sequencing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Research Institutes
    • 4.1.2 Hospitals & Clinics
    • 4.1.3 Biotechnology Company
    • 4.1.4 Diagnostic Lab
  • 4.2 Global Targeted RNA Sequencing Sales Value by Application
    • 4.2.1 Global Targeted RNA Sequencing Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Targeted RNA Sequencing Sales Value, by Application (2020-2031)
    • 4.2.3 Global Targeted RNA Sequencing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Targeted RNA Sequencing Sales Value by Region
    • 5.1.1 Global Targeted RNA Sequencing Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Targeted RNA Sequencing Sales Value by Region (2020-2025)
    • 5.1.3 Global Targeted RNA Sequencing Sales Value by Region (2026-2031)
    • 5.1.4 Global Targeted RNA Sequencing Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Targeted RNA Sequencing Sales Value, 2020-2031
    • 5.2.2 North America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Targeted RNA Sequencing Sales Value, 2020-2031
    • 5.3.2 Europe Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Targeted RNA Sequencing Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Targeted RNA Sequencing Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Targeted RNA Sequencing Sales Value, 2020-2031
    • 5.5.2 South America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Targeted RNA Sequencing Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Targeted RNA Sequencing Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Targeted RNA Sequencing Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.3.2 United States Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.4.2 Europe Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.5.2 China Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.6.2 Japan Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.7.2 South Korea Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Targeted RNA Sequencing Sales Value, 2020-2031
    • 6.9.2 India Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Targeted RNA Sequencing Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Thermo Fisher
    • 7.1.1 Thermo Fisher Profile
    • 7.1.2 Thermo Fisher Main Business
    • 7.1.3 Thermo Fisher Targeted RNA Sequencing Products, Services and Solutions
    • 7.1.4 Thermo Fisher Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Thermo Fisher Recent Developments
  • 7.2 Illumina
    • 7.2.1 Illumina Profile
    • 7.2.2 Illumina Main Business
    • 7.2.3 Illumina Targeted RNA Sequencing Products, Services and Solutions
    • 7.2.4 Illumina Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Illumina Recent Developments
  • 7.3 Roche Holdings
    • 7.3.1 Roche Holdings Profile
    • 7.3.2 Roche Holdings Main Business
    • 7.3.3 Roche Holdings Targeted RNA Sequencing Products, Services and Solutions
    • 7.3.4 Roche Holdings Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Roche Holdings Recent Developments
  • 7.4 BGI
    • 7.4.1 BGI Profile
    • 7.4.2 BGI Main Business
    • 7.4.3 BGI Targeted RNA Sequencing Products, Services and Solutions
    • 7.4.4 BGI Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.4.5 BGI Recent Developments
  • 7.5 Eurofins
    • 7.5.1 Eurofins Profile
    • 7.5.2 Eurofins Main Business
    • 7.5.3 Eurofins Targeted RNA Sequencing Products, Services and Solutions
    • 7.5.4 Eurofins Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Eurofins Recent Developments
  • 7.6 LabCorp
    • 7.6.1 LabCorp Profile
    • 7.6.2 LabCorp Main Business
    • 7.6.3 LabCorp Targeted RNA Sequencing Products, Services and Solutions
    • 7.6.4 LabCorp Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.6.5 LabCorp Recent Developments
  • 7.7 Berry Genomics
    • 7.7.1 Berry Genomics Profile
    • 7.7.2 Berry Genomics Main Business
    • 7.7.3 Berry Genomics Targeted RNA Sequencing Products, Services and Solutions
    • 7.7.4 Berry Genomics Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Berry Genomics Recent Developments
  • 7.8 Macrogen
    • 7.8.1 Macrogen Profile
    • 7.8.2 Macrogen Main Business
    • 7.8.3 Macrogen Targeted RNA Sequencing Products, Services and Solutions
    • 7.8.4 Macrogen Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Macrogen Recent Developments
  • 7.9 GENEWIZ
    • 7.9.1 GENEWIZ Profile
    • 7.9.2 GENEWIZ Main Business
    • 7.9.3 GENEWIZ Targeted RNA Sequencing Products, Services and Solutions
    • 7.9.4 GENEWIZ Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.9.5 GENEWIZ Recent Developments
  • 7.10 Natera
    • 7.10.1 Natera Profile
    • 7.10.2 Natera Main Business
    • 7.10.3 Natera Targeted RNA Sequencing Products, Services and Solutions
    • 7.10.4 Natera Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Natera Recent Developments
  • 7.11 Novogen
    • 7.11.1 Novogen Profile
    • 7.11.2 Novogen Main Business
    • 7.11.3 Novogen Targeted RNA Sequencing Products, Services and Solutions
    • 7.11.4 Novogen Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Novogen Recent Developments
  • 7.12 Pacific Biosciences
    • 7.12.1 Pacific Biosciences Profile
    • 7.12.2 Pacific Biosciences Main Business
    • 7.12.3 Pacific Biosciences Targeted RNA Sequencing Products, Services and Solutions
    • 7.12.4 Pacific Biosciences Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Pacific Biosciences Recent Developments
  • 7.13 Oxford Nanopore
    • 7.13.1 Oxford Nanopore Profile
    • 7.13.2 Oxford Nanopore Main Business
    • 7.13.3 Oxford Nanopore Targeted RNA Sequencing Products, Services and Solutions
    • 7.13.4 Oxford Nanopore Targeted RNA Sequencing Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Oxford Nanopore Recent Developments

8 Industry Chain Analysis

  • 8.1 Targeted RNA Sequencing Industrial Chain
  • 8.2 Targeted RNA Sequencing Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Targeted RNA Sequencing Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Targeted RNA Sequencing Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Targeted RNA Sequencing Market Trends
  • Table 2. Targeted RNA Sequencing Market Drivers & Opportunity
  • Table 3. Targeted RNA Sequencing Market Challenges
  • Table 4. Targeted RNA Sequencing Market Restraints
  • Table 5. Global Targeted RNA Sequencing Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Targeted RNA Sequencing Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Targeted RNA Sequencing Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Targeted RNA Sequencing Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Targeted RNA Sequencing
  • Table 10. Global Targeted RNA Sequencing Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted RNA Sequencing as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Targeted RNA Sequencing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Targeted RNA Sequencing Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Targeted RNA Sequencing Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Targeted RNA Sequencing Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Targeted RNA Sequencing Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Targeted RNA Sequencing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Targeted RNA Sequencing Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Targeted RNA Sequencing Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Targeted RNA Sequencing Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Targeted RNA Sequencing Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Targeted RNA Sequencing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Targeted RNA Sequencing Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Targeted RNA Sequencing Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Targeted RNA Sequencing Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Targeted RNA Sequencing Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Targeted RNA Sequencing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Targeted RNA Sequencing Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Targeted RNA Sequencing Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Thermo Fisher Basic Information List
  • Table 32. Thermo Fisher Description and Business Overview
  • Table 33. Thermo Fisher Targeted RNA Sequencing Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Targeted RNA Sequencing Business of Thermo Fisher (2020-2025)
  • Table 35. Thermo Fisher Recent Developments
  • Table 36. Illumina Basic Information List
  • Table 37. Illumina Description and Business Overview
  • Table 38. Illumina Targeted RNA Sequencing Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Targeted RNA Sequencing Business of Illumina (2020-2025)
  • Table 40. Illumina Recent Developments
  • Table 41. Roche Holdings Basic Information List
  • Table 42. Roche Holdings Description and Business Overview
  • Table 43. Roche Holdings Targeted RNA Sequencing Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Targeted RNA Sequencing Business of Roche Holdings (2020-2025)
  • Table 45. Roche Holdings Recent Developments
  • Table 46. BGI Basic Information List
  • Table 47. BGI Description and Business Overview
  • Table 48. BGI Targeted RNA Sequencing Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Targeted RNA Sequencing Business of BGI (2020-2025)
  • Table 50. BGI Recent Developments
  • Table 51. Eurofins Basic Information List
  • Table 52. Eurofins Description and Business Overview
  • Table 53. Eurofins Targeted RNA Sequencing Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Targeted RNA Sequencing Business of Eurofins (2020-2025)
  • Table 55. Eurofins Recent Developments
  • Table 56. LabCorp Basic Information List
  • Table 57. LabCorp Description and Business Overview
  • Table 58. LabCorp Targeted RNA Sequencing Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Targeted RNA Sequencing Business of LabCorp (2020-2025)
  • Table 60. LabCorp Recent Developments
  • Table 61. Berry Genomics Basic Information List
  • Table 62. Berry Genomics Description and Business Overview
  • Table 63. Berry Genomics Targeted RNA Sequencing Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Targeted RNA Sequencing Business of Berry Genomics (2020-2025)
  • Table 65. Berry Genomics Recent Developments
  • Table 66. Macrogen Basic Information List
  • Table 67. Macrogen Description and Business Overview
  • Table 68. Macrogen Targeted RNA Sequencing Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Targeted RNA Sequencing Business of Macrogen (2020-2025)
  • Table 70. Macrogen Recent Developments
  • Table 71. GENEWIZ Basic Information List
  • Table 72. GENEWIZ Description and Business Overview
  • Table 73. GENEWIZ Targeted RNA Sequencing Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Targeted RNA Sequencing Business of GENEWIZ (2020-2025)
  • Table 75. GENEWIZ Recent Developments
  • Table 76. Natera Basic Information List
  • Table 77. Natera Description and Business Overview
  • Table 78. Natera Targeted RNA Sequencing Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Targeted RNA Sequencing Business of Natera (2020-2025)
  • Table 80. Natera Recent Developments
  • Table 81. Novogen Basic Information List
  • Table 82. Novogen Description and Business Overview
  • Table 83. Novogen Targeted RNA Sequencing Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Targeted RNA Sequencing Business of Novogen (2020-2025)
  • Table 85. Novogen Recent Developments
  • Table 86. Pacific Biosciences Basic Information List
  • Table 87. Pacific Biosciences Description and Business Overview
  • Table 88. Pacific Biosciences Targeted RNA Sequencing Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Targeted RNA Sequencing Business of Pacific Biosciences (2020-2025)
  • Table 90. Pacific Biosciences Recent Developments
  • Table 91. Oxford Nanopore Basic Information List
  • Table 92. Oxford Nanopore Description and Business Overview
  • Table 93. Oxford Nanopore Targeted RNA Sequencing Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Targeted RNA Sequencing Business of Oxford Nanopore (2020-2025)
  • Table 95. Oxford Nanopore Recent Developments
  • Table 96. Key Raw Materials Lists
  • Table 97. Raw Materials Key Suppliers Lists
  • Table 98. Targeted RNA Sequencing Downstream Customers
  • Table 99. Targeted RNA Sequencing Distributors List
  • Table 100. Research Programs/Design for This Report
  • Table 101. Key Data Information from Secondary Sources
  • Table 102. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Targeted RNA Sequencing Product Picture
  • Figure 2. Global Targeted RNA Sequencing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Targeted RNA Sequencing Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Targeted RNA Sequencing Report Years Considered
  • Figure 5. Global Targeted RNA Sequencing Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Targeted RNA Sequencing Revenue in 2024
  • Figure 7. Targeted RNA Sequencing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Exome Sequencing Picture
  • Figure 9. Enrichment Sequencing Picture
  • Figure 10. Amplicon Sequencing Picture
  • Figure 11. Global Targeted RNA Sequencing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Targeted RNA Sequencing Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Research Institutes
  • Figure 14. Product Picture of Hospitals & Clinics
  • Figure 15. Product Picture of Biotechnology Company
  • Figure 16. Product Picture of Diagnostic Lab
  • Figure 17. Global Targeted RNA Sequencing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Targeted RNA Sequencing Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Targeted RNA Sequencing Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Targeted RNA Sequencing Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Targeted RNA Sequencing Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Targeted RNA Sequencing Sales Value (%), (2020-2031)
  • Figure 30. United States Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Targeted RNA Sequencing Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Targeted RNA Sequencing Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Targeted RNA Sequencing Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Targeted RNA Sequencing Industrial Chain
  • Figure 52. Targeted RNA Sequencing Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed